Haematological malignancies in older adults: Experience in a geriatric acute care department;Hémopathies et sujets âgés : expérience d'un service de court séjour gériatrique

Revue de Medecine Interne

Volumn 29, Issue 7, 2008, Pages 541-549

  Rollot Trad, F ^a,b   Lahjibi, H ^b   Lazarovici, C ^a   Bauer, C ^a   Saint Jean, O ^a   Gisselbrecht, M ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b hôpital Cochin ^*  (France)

Author keywords

Blood disease; Elderly; Lymphoma; Mortality; Nutrition

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

AGED; ALBUMIN BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; BRONCHOSPASM; COMORBIDITY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; FEMALE; GERIATRIC CARE; GERIATRIC HOSPITAL; HEMATOLOGIC MALIGNANCY; HOSPITAL DISCHARGE; HUMAN; INFECTION; LIFESTYLE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; NUTRITIONAL STATUS; PANCREAS DISEASE; SCORING SYSTEM; SURVIVAL RATE; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; FEMALE; FRANCE; HEALTH SERVICES FOR THE AGED; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; NEOPLASM STAGING; SURVIVAL ANALYSIS;

EID: 45849109937     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2007.12.015     Document Type: Article

References (37)

1. Institut de veille sanitaire. Estimation de l'incidence et de la mortalité par cancer en France de 1978 à 2000. http://www.invs.sante.fr/estimations_cancer/pages/donnees_generales/parage/repar_age.htm. - Mise à jour le 28 août 2007.
2. Institut national du cancer. Bilan cancer 2003-2006. Une prise en charge adaptée aux enfants, aux adolescents et aux personnes âgées. Chapitre 4-5, pages 116 à 118 - http://www.ecancer.fr/v1/fichiers/public/6_bilan_plan_cancer_soins.pdf.
3. Hutchins L.F., Unger J.M., Crowley J.J., Coltman Jr. C.A., and Albain K.S. Under representation of patients 65 years of age or older in cancer treatment trials. N Engl J Med 341 (1999) 2061-2067
4. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
5. Rodon P., Linassier C., Gauvain J.B., Benboubker L., Goupille P., Maigre M., et al. Multiple myeloma in elderly patients: presenting features and outcome. Eur J Haematol 66 (2001) 11-17
6. Crighton M.H., and Puppione A.A. Geriatric neutrophils: implications for older adults. Semin Oncol Nurs 22 (2006) 3-9
7. Bordonaro R., Fratino L., and Serraino D. Treatment of non-Hodgkin's lymphomas in elderly patients. Clin Lymphoma 5 (2004) 37-44
8. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
9. Doorduijn J., Buijt I., Holt B., Steijaert M., Uyl-de Groot C., and Sonneveld P. Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy. Eur J Haematol 75 (2005) 116-123
10. Catenacci D.V., and Schiller G.J. Myelodysplasic syndromes: a comprehensive review. Blood Rev 19 (2005) 301-319
11. Gelsi-Boyer V., and Vey N. Recent advances in the treatment of myelodysplastic syndromes. Rev Med Interne 27 (2006) 600-609
12. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., Ahlgren T., Dahl I.M., Dybedal I., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120 (2003) 1037-1046
13. Palumbo A., Bringhen S., Caravita T., Merla E., Capparella V., Callea V., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 (2006) 825-831
14. Facon T., Mary J.Y., Pegourie B., Attal M., Renaud M., Sadoun A., et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 107 (2006) 1292-1298
15. Dimopoulos M.A., Anagnostopoulos A., Terpos E., Repoussis P., Zomas A., Katodritou E., et al. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica 91 (2006) 252-254
16. Mateos M.V., Hernandez J.M., Hernandez M.T., Gutierrez N.C., Palomera L., Fuertes M., et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108 (2006) 2165-2172
17. Tralongo P., Repetto L., Di Mari A., Mauceri G., Bollina R., Ferrau F., et al. Safety of long-term administration of bisphosphonates in elderly cancer patients. Oncology 67 (2004) 112-116
18. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
19. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (2006) 2408-2417
20. Finazzi G., Caruso V., Marchioli R., Capnist G., Chisesi T., Finelli C., et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 105 (2005) 2664-2670
21. Griesshammer M. Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia. Semin Thromb Hemost 32 (2006) 372-380
22. Engert A., Ballova V., Haverkamp H., Pfistner B., Josting A., Duhmke E., et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 23 (2005) 5052-5060
23. Landgren O., Axdorph U., Fears T.R., Porwit-MacDonald A., Wedelin C., and Bjorkholm M. A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients. Ann Oncol 17 (2006) 1290-1295
24. Feltl D., Vitek P., and Zamecnik J. Hodgkin's lymphoma in the elderly: the results of 10 years of follow-up. Leuk Lymphoma 47 (2006) 1518-1522
25. Diehl L.F., Karnell L.H., and Menck H.R. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer 86 (1999) 2684-2692
26. O'Brien S., Kantarjian H., Beran M., Koller C., Talpaz M., Lerner S., et al. Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 11 (1997) 1631-1635
27. Robak T., Blasinska-Morawiec M., Blonski J.Z., and Dmoszynska A. 2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 34 (1999) 151-157
28. D'Arena G., Laurenti L., Capalbo S., D'Arco A.M., De Filippi R., Marcacci G., et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 81 (2006) 598-602
29. Gardin C., Turlure P., Fagot T., Thomas X., Terre C., Contentin N., et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 109 (2007) 5129-5135
30. Melchert M. Managing acute myeloid leukemia in the elderly. Oncology 20 (2006) 1674-1682
31. Jentsch-Ullrich K., Pelz A.F., Braun H., Koenigsmann M., Mohren M., Wieacker P., et al. Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib. Haematologica 89 (2004) ECR15
32. Delannoy A., Delabesse E., Lheritier V., Castaigne S., Rigal-Huguet F., Raffoux E., et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 20 (2006) 1526-1532
33. Deschler B., de Witte T., Mertelsmann R., and Lubbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 91 (2006) 1513-1522
34. Chen-Hardee S., Chrischilles E.A., Voelker M.D., Brooks J.M., Scott S., Link B.K., et al. Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). Cancer Causes Control 17 (2006) 647-654
35. Gomez H., Mas L., Casanova L., Pen D.L., Santillana S., Valdivia S., et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 16 (1998) 2352-2358
36. Repetto L., Biganzoli L., Koehne C.H., Luebbe A.S., Soubeyran P., Tjan-Heijnen V.C., et al. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 39 (2003) 2264-2272
37. Doorduijn J.K., van der Holt B., van Imhoff G.W., van der Hem K.G., Kramer M.H., van Oers M.H., et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 21 (2003) 3041-3050